Gomes Pedro, Soares-da-Silva Patrício
Institute of Pharmacology and Therapeutics, Faculty of Medicine, Porto 4200-319, Portugal.
Eur J Pharmacol. 2004 Mar 19;488(1-3):51-9. doi: 10.1016/j.ejphar.2004.02.011.
Dopamine D(1)-mediated inhibition of Na(+),K(+)-ATPase activity in opossum kidney (OK) cells involves the sequential activation of the adenylyl cyclase-protein kinase A (PKA) and the phospholipase C-protein kinase C (PKC) pathways. The present study evaluated the signalling cascades involved in dopamine-mediated inhibition of Na(+)/H(+) exchanger isoform 3 (NHE3) in OK cells. The transport kinetics displayed a simple Michaelis-Menten relationship for extracellular Na(+) of 25+/-6 mM. Dopamine and the dopamine D(1)-like receptor agonist SKF 38393 ((+/-)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol) inhibited NHE3 activity in a concentration-dependent manner; the dopamine D(2)-like receptor agonist quinerolane was devoid of effect. The SKF 38393-mediated inhibition of NHE3 was prevented either by the dopamine D(1)-like receptor antagonist SKF 83566 ((+/-)-7-Bromo-8-8-hydroxy-3 methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; 1 microM), overnight treatment with cholera toxin (500 ng/ml), the PKA antagonist H-89 (N-(2-[p-bromocinnamylamino]ethyl)-5 isoquinolinesulfonamide hydrochloride; 10 microM), the PKC antagonist chelerythrine (1 microM), or the phospholipase C inhibitor U-73,122 (1-(6-[(17beta]-3-methoxyestra-1,3,5[10]-trien-17-yl) amino] hexyl)-1H-pyrrole-2,5-dione; 3 microM). In addition, dibutyril cAMP (dB-cAMP; 500 microM) was found to increase phospholipase C activity, both in membranes and in cytosol from OK cells; in contrast, phorbol-12,13-dibutyrate (PDB) (1 microM) did not have a significant effect on phospholipase C activity. Pre-treatment of OK cells with the anti-G(s)alpha antibody, but not the anti-G(q/11)alpha antibody, blunted the inhibitory effect of SKF 38393 on NHE3 activity. It is concluded that dopamine D(1)-mediated inhibition of NHE3 in renal OK cells involves both adenylyl cyclase-PKA and the phospholipase C-PKC pathways, a mechanism similar to that described for Na(+),K(+)-ATPase.
多巴胺D(1)介导的对负鼠肾(OK)细胞中Na(+)、K(+)-ATP酶活性的抑制作用涉及腺苷酸环化酶-蛋白激酶A(PKA)和磷脂酶C-蛋白激酶C(PKC)途径的顺序激活。本研究评估了OK细胞中多巴胺介导的对Na(+)/H(+)交换体亚型3(NHE3)抑制作用所涉及的信号级联反应。对于25±6 mM的细胞外Na(+),转运动力学呈现出简单的米氏关系。多巴胺和多巴胺D(1)样受体激动剂SKF 38393((±)-1-苯基-2,3,4,5-四氢-(1H)-3-苯并氮杂卓-7,8-二醇)以浓度依赖性方式抑制NHE3活性;多巴胺D(2)样受体激动剂喹尼罗烷则无此作用。SKF 38393介导的对NHE3的抑制作用可被多巴胺D(1)样受体拮抗剂SKF 83566((±)-7-溴-8-羟基-3-甲基-1-苯基-2,3,4,5-四氢-1H-3-苯并氮杂卓;1 μM)、用霍乱毒素(500 ng/ml)过夜处理、PKA拮抗剂H-89(N-(2-[对溴肉桂基氨基]乙基)-5-异喹啉磺酰胺盐酸盐;10 μM)、PKC拮抗剂白屈菜红碱(1 μM)或磷脂酶C抑制剂U-73122(1-(6-[(17β]-3-甲氧基雌甾-1,3,5[10]-三烯-17-基)氨基]己基)-1H-吡咯-2,5-二酮;3 μM)所阻断。此外,发现二丁酰环磷腺苷(dB-cAMP;500 μM)可增加OK细胞膜和胞质溶胶中的磷脂酶C活性;相反,佛波醇-12,13-二丁酸酯(PDB)(1 μM)对磷脂酶C活性无显著影响。用抗G(s)α抗体而非抗G(q/11)α抗体预处理OK细胞,可减弱SKF 38393对NHE3活性的抑制作用。结论是,多巴胺D(1)介导的对肾OK细胞中NHE3的抑制作用涉及腺苷酸环化酶-PKA和磷脂酶C-PKC途径,这一机制与Na(+)、K(+)-ATP酶的情况类似。